NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy

SIMPLE SUMMARY: eIF4A-targeted translational inhibitors, such as silvestrol and its analogues, have emerged as strong anticancer therapies. Here, we tested the efficacy of eIF4A inhibition across a large and diverse panel of cancer cell lines and found B cell lymphomas to be the most sensitive group...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Sanghvi, Viraj R., Mohan, Prathibha, Singh, Kamini, Cao, Linlin, Berishaj, Marjan, Wolfe, Andrew L., Schatz, Jonathan H., Lailler, Nathalie, de Stanchina, Elisa, Viale, Agnes, Wendel, Hans-Guido
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7915661/
https://ncbi.nlm.nih.gov/pubmed/33562682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040639
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires